Close Menu
    News

    Hims & Hers falls 8% as FDA issues warning letter over compounded weight loss drug

    Press RoomBy No Comments1 Min Read
    Two packages of 5 dosing pens each of a fictitious Semiglutin drug used for weight loss (antidiabetic medication or anti-obesity medication) on a blue transparent background. Fictitious package design

    aprott/iStock via Getty Images

    • The U.S. FDA has issued a warning letter to Hims & Hers Health (NYSE:HIMS) over its marketing of compounded semaglutide, the weight loss drug marketed under the brand name Wegovy by Novo Nordisk (NVO).
    • Shares of Hims & Hers are
    Share.

    Related Posts

    Leave A Reply